Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026$535 million in cash, cash equivalents and short-term investments as of ...

Company rapidly advancing Phase 3 programs designed to deliver best-in-class efficacy with convenient quarterly dosing in ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its business update and consolidated financial results for the quarter ending March 31, 2026. "We have ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 7:20 PM EDTCompany ParticipantsMegan Sniecinski ...

First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agency ...

A mitochondrial peptide that mimics exercise? The data are surprising. I went down the rabbit hole—and now I’m testing it ...

Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...